...
首页> 外文期刊>Journal of child and adolescent psychopharmacology >Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in germany: Results from a large population-based cohort study
【24h】

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in germany: Results from a large population-based cohort study

机译:德国儿童和青少年注意力缺乏/多动障碍的药物治疗模式:一项基于人群的大型队列研究结果

获取原文
获取原文并翻译 | 示例

摘要

Objective: Despite a substantial increase in total methylphenidate (MPH) prescriptions in Germany over the last 20 years, and the introduction of modified release MPH (MR MPH) and atomoxetine (ATX), remarkably little is known about treatment patterns of attention-deficit/hyperactivity disorder (ADHD) in individual patients. Methods: Usage patterns of ADHD drugs in children and adolescents in Germany were analyzed using data from one large German health insurance including >7,200,000 members. Of those, 6210 ADHD patients newly diagnosed in 2005 were followed for a maximum of 4 years. Kaplan-Meier estimates were calculated for onset and discontinuation of ADHD drug treatment. Predictors of time until drug treatment initiation were assessed by Cox regression. Results: During follow-up, 52.0% of ADHD subjects (53.4% of boys, 47.5% of girls) received ADHD drug treatment. The majority of them (91.6%) were started on MPH, with immediate release MPH (IR MPH) being the initial treatment choice in 75.3%. In these subjects, change to drug treatment with MR MPH in the first year occurred in 48% by switch or addition. Significant predictors of drug treatment were behavioral and emotional disorders (HR=1.13; 95% CI 1.03-1.24) and a diagnosis of ADHD with conduct disorder (HR=1.21, 95% CI 1.12-1.32), whereas young age showed a protective effect. After 6, 12, and 24 months of treatment initiation, 22.4%, 43.4%, and 66.3% of treated girls, and 17.8%, 36.1%, and 54.1% of treated boys had discontinued ADHD treatment. Conclusion: Drug treatment of ADHD was relatively common in Germany and more frequent in boys than in girls. IR MPH was the predominant treatment choice at treatment initiation. Approximately 20% of treated subjects discontinued drug treatment within the first 6 months, with girls stopping drug treatment earlier than boys. The reasons for early drug discontinuation need to be further explored.
机译:目标:尽管在过去20年中,德国的哌醋甲酯(MPH)处方总量大幅增加,并且引入了缓释MPH(MR MPH)和阿托西汀(ATX),但对于注意力缺陷/多动症(ADHD)的个别患者。方法:使用来自包括720万名会员的大型德国医疗保险的数据,分析了德国儿童和青少年ADHD药物的使用模式。其中,对2005年新诊断的6210名多动症患者进行了长达4年的随访。计算出ADHD药物治疗的起效和中止的Kaplan-Meier估计。通过Cox回归评估药物治疗开始之前的时间预测因子。结果:在随访期间,有52.0%的ADHD受试者(男孩53.4%,女孩47.5%)接受了ADHD药物治疗。他们中的大多数(91.6%)是从MPH开始服用的,其中75.3%的患者最初选择立即释放MPH(IR MPH)。在这些受试者中,第一年通过切换或加用MR MPH进行药物治疗的变化为48%。药物治疗的重要预测指标是行为和情绪障碍(HR = 1.13; 95%CI 1.03-1.24)和诊断为多动症的品行障碍(HR = 1.21,95%CI 1.12-1.32),而青年人显示出保护作用。在开始治疗的6、12和24个月后,分别有22.4%,43.4%和66.3%的被治疗女孩以及17.8%,36.1%和54.1%的被治疗男孩停止了ADHD治疗。结论:德国多动症的药物治疗相对普遍,男孩比女孩多见。 IR MPH是治疗开始时的主要治疗选择。大约20%的接受治疗的受试者在头6个月内停止药物治疗,女孩比男孩更早地停止药物治疗。早期停药的原因有待进一步探讨。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号